**6. References**


The Use of Antihypertensive Medicines in Primary Health Care Settings 149

[19] Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. 2004. The burden of adult

[20] Gaziano TA. 2005. Cardiovascular disease in the developing world and its cost-effective

[21] Health Action International, HAI. Monitoring medicine prices, availability and

http://www.haiweb.org/medicineprices/. Accessed on: December 20, 2011 [22] Ho PM, Zeng C, Tavel HM, Selby JV, O'Connor PJ, Margolis KL, Magid DJ. 2010.

Network Hypertension Registry, 2002-2007. Arch Intern Med 170(10):912-3. [23] Jackson PR, Ramsay LE. 2002. First-line treatment for hypertension. Eur Heart J

[24] Jha P, Chaloupka F. 1999. Tobacco control in developing countries. On behalf of The

Service, World Health Organization. New York: Oxford University Press. [25] John KJ Li. 2000. The arterial circulation : physical principals and clinical application.

[26] Johnson JA. 2008. Ethnic differences in cardiovascular drug response: Potential

[27] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455):217-23. [28] Khosla N, Black HR. 2006. Expanding the definition of hypertension to incorporate

[29] Lawes CM, Vander HS, Rodgers A. 2008. Global burden of blood-pressure-related

[30] Lindholm LH, Carlberg B, Samuelsson O. 2005. Should beta blockers remain first choice

[31] Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and regional

[32] MacDonald TM, Morant SV. 2008. Prevalence and treatment of isolated and concurrent

[33] Management Sciences for Health (MSH), World Health Organization (WHO). 2007. International drug price indicator guide 2007. 2007 ed. MSH, WHO. 1 p. [34] Mancia G, de BG, Dominiczak A, Cifkova R, Fagard RH, Germano G, Grassi G,

in the treatment of primary hypertension? A meta-analysis. Lancet 366(9496):1545-

burden of disease and risk factors, 2001: systematic analysis of population health

hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin

Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Gabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Gabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip GY, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, Van Zwieten P, Waeber B,

contribution of pharmacogenetics. Circulation 118(13):1383-93.

global cardiovascular risk. Curr Hypertens Rep 8(5):384-90.

44(4):398-404.

23(3):179-82.

53.

management. Circulation 112(23):3547-53.

Piscataway, New Jersey, USA: Humana Press. 1 p.

disease, 2001. Lancet 371(9623):1513-8.

data. Lancet 367(9524):1747-57.

Pharmacol 65(5):775-86.

hypertension in the United States 1999 to 2000: a rising tide. Hypertension

affordability : pilot countries' reports. HAI 2008;Available from: URL:

Trends in first-line therapy for hypertension in the Cardiovascular Research

Human Development Network, the World Bank, and the Economics Advisory

comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. Journal of the American Medical Association 289(16):2083- 93.


[5] Birkett NJ. 1997. The effect of alternative criteria for hypertension on estimates of

[6] Bovet P, Ross AG, Gervasoni JP, Mkamba M, Mtasiwa DM, Lengeler C, Whiting D,

socioeconomic status. International Journal of Epidemiology 31(1):240-7. [7] Brewster LM, Van Montfrans GA, Kleijnen J. 2004. Systematic review: Antihypertensive drug therapy in black patients. Annals of Internal Medicine 141(8):614-27. [8] Cappuccio FP, Plange-Rhule J, Phillips RO, Eastwood JB. 2000. Prevention of

[9] Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, Pinel J. 2008. Substandard

[10] Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers

[12] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW,

[14] Cooper RS, Rotimi CN, Kaufman JS, Muna WF, Mensah GA. 1998. Hypertension

[15] De Maeseneer J. 2009. Primary Health Care in Africa: Now more then ever! Afr J Prm

[16] De Maeseneer J., Roberts RG, Demarzo M, Heath I, Sewankambo N, Kidd MR, van WC,

[17] Dominguez LJ, Galioto A, Ferlisi A, Pineo A, Putignano E, Belvedere M, Costanza G,

developing countries. Journal of Nutrition, Health & Aging 10(2):143-9. [18] Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA,

prevalence and control. J Hypertens 15(3):237-44.

hypertension and stroke in Africa. Lancet 356(9230):677-8.

Tropical Medicine and International Health 13(8):1062-72.

[13] Christiaens T. 2008. Cardiovascular risk tables. BMJ 336(7659):1445-6.

93.

J Anaesth 53(4):421-2.

Association 289(19):2560-72.

British Medical Journal 316(7131):614-7.

Health Care Fam Med 1(1):112-5.

Internal Medicine 163(5):525-41.

needed. Lancet.

comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. Journal of the American Medical Association 289(16):2083-

Paccaud F. 2002. Distribution of blood pressure, body mass index and smoking habits in the urban population of Dar es Salaam, Tanzania, and associations with

medicines in resource-poor settings: a problem that can no longer be ignored.

A, Ni MC, Clark T. 1999. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines subcommittee of the World Health Organization. Clin Exp Hypertens 21(5-6):1009-60. [11] Chemla D. 2006. Factors which may influence mean arterial pressure measurement. Can

Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. 2003. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Journal of the American Medical

treatment and control in sub-Saharan Africa: The epidemiological basis for policy.

Egilman D, Boelen C, Willems S. 2011. Tackling NCDs: a different approach is

Barbagallo M. 2006. Ageing, lifestyle modifications, and cardiovascular disease in

Jones WE, Haywood LJ, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG. 2003. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Archives of


The Use of Antihypertensive Medicines in Primary Health Care Settings 151

[50] Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Bray GA, Vogt

[51] Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den HE, Libhaber C,

Johannesburg, South Africa. Archives of Internal Medicine 161(7):965-71. [52] Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH, Karanja NM,

[53] Twagirumukiza M, Annemans L, Kips JG, Bienvenu E, Van Bortel LM. 2010. Prices of

[54] Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet C, Van BL. 2009a.

[55] Twagirumukiza M, De Bacquer D, Kips J, vander Stichele R, De Backer G, Van Bortel

[56] Twagirumukiza M, De BD, Kips JG, de BG, Stichele RV, Van Bortel LM. 2011. Current

and habitat: an estimate from population studies. J Hypertens 29(7):1243-52. [57] Twagirumukiza M, Van Bortel LM. 2011. Management of hypertension at the

[58] Unwin N, Setel P, Rashid S, Mugusi F, Mbanya JC, Kitange H, Hayes L, Edwards R,

[59] Van Bortel LM, De BT, De BM. 2011. How to treat arterial stiffness beyond blood

[60] Whitworth JA. 2003. 2003 World Health Organization (WHO)/International Society of

[61] World Health Organization. 2007. The selection and use of essential medicines 2007. 15th Model list of essential medicines. WHO Technical Report Series(946):1-162.

list of essential medicines. Trop Med Int Health 15(3):350-61.

from Rwandan pharmacies. Am J Trop Med Hyg 81(5):776-81.

American Heart Association. Circulation 123(4):e18-e209.

(DASH) Study. Clinical Cardiology 22(7 Suppl):III6-10.

Suppl):S96-104.

Risk. J Hypertens 27:S410.

Organization 79(10):947-53.

Hypertension 21(11):1983-92.

resources. J Hum Hypertens 25(1):47-56.

pressure lowering? J Hypertens 29(6):1051-3.

JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. 2011. Heart disease and stroke statistics-2011 update: a report from the

TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. 1999. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension

Skudicky D, Wang JG, Staessen JA. 2001. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in

Harsha DW, Bray GA, Aickin M, Proschan MA, Windhauser MM, Swain JF, McCarron PB, Rhodes DG, Laws RL. 1999. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. Journal of American Dietetic Association 99(8

antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model

Influence of tropical climate conditions on the quality of antihypertensive drugs

LM. 2009b. Hypertension in sub-Saharan Africa (SSA): Low Prevalence, But High

and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age

community level in sub-Saharan Africa (SSA): towards a rational use of available

Aspray T, Alberti KG. 2001. Noncommunicable diseases in sub-Saharan Africa: Where do they feature in the health research agenda? Bulletin of the World Health

Hypertension (ISH) statement on management of hypertension. Journal of

Williams B. 2007. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 25(6):1105-87.


[35] Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, Heagerty T. 2007.

[36] Mensah GA. 2003. A heart-healthy and "stroke-free" world through policy

[37] Mensah GA, Barkey NL, Cooper RS. 1994. Spectrum of hypertensive target organ

[38] Mufunda J, Rufaro Chatora, Yustina Ndambakuwa, Peter Nyarango ea. 2006. Emerging

[39] Murray CJ, Lopez AD. 1997. Mortality by cause for eight regions of the world: Global

[40] Ndiaye P, Soors W, Criel B. 2007. Editorial: a view from beneath: Community health insurance in Africa. Tropical Medicine and International Health 12(2):157-61. [41] Nichols WW., O'Rourke MF., Vlachopoulos C. 2011. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. Oxford Univ Pr. [42] O'Riordan S, Mackson J, Weekes L. 2008. Self-reported prescribing for hypertension in

[43] Opie LH, Seedat YK. 2005. Hypertension in sub-Saharan African populations.

[44] Papadopoulos DP, Makris TK. 2007. Masked hypertension definition, impact, outcomes:

[45] Pestana JA, Steyn K, Leiman A, Hartzenberg GM. 1996. The direct and indirect costs of

[46] Pittrow D, Kirch W, Bramlage P, Lehnert H, Hofler M, Unger T, Sharma AM, Wittchen

[47] Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC,

[48] Reddy KS, Yusuf S. 1998. Emerging epidemic of cardiovascular disease in developing

[49] Roger VL., Go AS., Lloyd-Jones DM., Adams RJ, Berry JD, Brown TM, Carnethon MR,

cardiovascular disease in South Africa in 1991. South African Medical Journal

HU. 2004. Patterns of antihypertensive drug utilization in primary care. Eur J Clin

Anderson RJ. 1998. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Journal of the

Dai S, de SG, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman

a critical review. J Clin Hypertens (Greenwich ) 9(12):956-63.

Journal of Hypertension 25(6):1105-87.

Saharan Africa. Ethn Dis 13(2 Suppl 2):S4-12.

WHO Regional Office for Africa. Ethn Dis 16(2):521-6.

Burden of Disease Study. Lancet 349(9061):1269-76.

general practice. J Clin Pharm Ther 33(5):483-8.

American Medical Association 280(13):1168-72.

countries. Circulation 97(6):596-601.

Circulation 112(23):3562-8.

Pharmacol 60(2):135-42.

86(6):679-84.

25(8):1578-82.

8(11):799-808.

Williams B. 2007. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens

development, systems change, and environmental supports: a 2020 vision for sub-

damage in Africa: a review of published studies. Journal of Human Hypertension

Non-Communicable Disease Epidemic in Africa: Preventive Measures from the

JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. 2011. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123(4):e18-e209.


[62] World Health Organization, J Mackay, G.Mensah. The Atlas of Heart Disease and

[63] World Health Organization (WHO). 2002. CVD-Risk Management Package for Low and

[64] World Hypertension League. 1992. Can non-pharmacological interventions reduce

[65] Wright JT, Jr., Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ,

[66] Wright JT, Jr., Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile

Attack Trial (ALLHAT). Archives of Internal Medicine 168(2):207-17.

doses of drugs needed for the treatment of hypertension? Bulletin of the World

Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB. 2005. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Journal of the American Medical

JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZ, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, Davis BR. 2008. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart

Medium Resource Settings. Geneva: WHO; 7 p. Available from.

Stroke, 2004. WHO. 1-112. 2004. Geneva, WHO.

Health Organization 70(6):685-90.

Association 293(13):1595-608.
